KAREN SUE ANDERSON MD PHD NPI 1396712089

NPI Details

Karen Sue Anderson, MD PHD is a hematology and oncology internal medicine in Scottsdale, AZ with 31 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. Karen Sue Anderson, MD PHD NPI is 1396712089. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a female.

Education
Medical School: DUKE UNIVERSITY SCHOOL OF MEDICINE
Graduation Year:1994

The provider's business location address is:

13400 E SHEA BLVD
SCOTTSDALE, AZ
ZIP 85259-452
Phone: (480) 301-8000

The NPI 1396712089 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, fosaprepitant, 1 mg (HCPCS:J1453)
• Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS:Q5110)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, darbepoetin alfa, 1 microgram (non-esrd use) (HCPCS:J0881)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, carfilzomib, 1 mg (HCPCS:J9047)
• Injection, ondansetron hydrochloride, per 1 mg (HCPCS:J2405)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg (HCPCS:J1569)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Injection, decitabine, 1 mg (HCPCS:J0894)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, etoposide, 10 mg (HCPCS:J9181)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Leuprolide acetate (for depot suspension), 7.5 mg (HCPCS:J9217)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Collection of blood sample from implanted device (HCPCS:36591)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion (HCPCS:96368)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)

The enumeration date for this NPI number is 3/2/2006 and was last updated on 9/9/2020.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: